Alliancebernstein L.P. reduced its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 11.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,540 shares of the biotechnology company’s stock after selling 2,500 shares during the period. Alliancebernstein L.P.’s holdings in Atara Biotherapeutics were worth $381,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. American International Group Inc. boosted its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the period. Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Atara Biotherapeutics during the first quarter worth $555,000. Parametric Portfolio Associates LLC raised its position in shares of Atara Biotherapeutics by 62.6% in the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock worth $522,000 after buying an additional 9,774 shares in the last quarter. Eagle Asset Management Inc. raised its position in shares of Atara Biotherapeutics by 14.1% in the first quarter. Eagle Asset Management Inc. now owns 1,267,609 shares of the biotechnology company’s stock worth $26,049,000 after buying an additional 156,911 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Atara Biotherapeutics by 9.6% in the first quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock worth $588,000 after buying an additional 2,500 shares in the last quarter. 81.50% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics, Inc. (ATRA) traded up 1.72% on Friday, reaching $14.75. 146,964 shares of the company traded hands. The stock has a 50 day moving average of $15.02 and a 200-day moving average of $15.89. Atara Biotherapeutics, Inc. has a 1-year low of $11.80 and a 1-year high of $23.40. The stock’s market capitalization is $450.75 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05. On average, equities analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.88) EPS for the current year.

WARNING: “Alliancebernstein L.P. Has $381,000 Stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/alliancebernstein-l-p-has-381000-stake-in-atara-biotherapeutics-inc-nasdaqatra/1478849.html.

Several equities analysts have commented on the stock. Canaccord Genuity reiterated a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, April 21st. ValuEngine lowered shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, June 22nd. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $25.75.

In other news, EVP Christopher Haqq sold 6,000 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $12.65, for a total transaction of $75,900.00. Following the sale, the executive vice president now owns 368,080 shares of the company’s stock, valued at $4,656,212. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gad Soffer sold 12,674 shares of the stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $15.16, for a total transaction of $192,137.84. Following the sale, the executive vice president now directly owns 259,527 shares in the company, valued at approximately $3,934,429.32. The disclosure for this sale can be found here. Insiders have sold 54,308 shares of company stock worth $797,382 in the last three months. Corporate insiders own 16.10% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.